Wendy Chung and the natural-history-first model

The KIF1A-Associated Neurological Disorders (KAND) Natural History Study is a registry of more than 600 affected individuals worldwide who carry damaging mutations in KIF1A, a gene encoding a kinesin motor protein essential for axonal transport. The study tracks longitudinal clinical data, genotype, neuroimaging, and outcome measures, and it is the central scientific resource for any program developing a therapy for KAND. The study sits in Wendy Chung's lab at Boston Children's Hospital. Its existence is the precondition for the n-of-1 antisense oligonucleotide trial Chung's program is now running for one KAND patient and for the broader trial work other groups are designing for the rest.

Chung's argument, which she has made publicly for fifteen years, is that natural-history data has to come first. Without it, no clinical trial can interpret a treated patient's trajectory, no regulator can evaluate whether a single-patient outcome is clinically meaningful, and no foundation can prioritize which mutations to target. The KAND study is the working example of what natural-history-first looks like when one academic group commits to building it.

Training

Chung earned a Ph.D. in genetics from Rockefeller University in 1996 and an M.D. from Cornell University Medical College in 1998. She completed her internship and residency in pediatrics at NewYork-Presbyterian Hospital, Columbia University Medical Center, followed by two clinical fellowships at the same institution, in molecular genetics and clinical genetics.

She joined the Columbia faculty after fellowship and rose to become Chief of the Division of Clinical Genetics within the Department of Pediatrics at Columbia University Irving Medical Center and NewYork-Presbyterian Morgan Stanley Children's Hospital. In 2023 she became Chair of the Department of Pediatrics at Boston Children's Hospital and Professor at Harvard Medical School. The move brought her primary academic affiliation, the Chung Lab, and the natural-history programs the lab runs to Boston Children's.

The Chung Lab

The Chung Lab works on the genetic basis of human disease across an unusually wide range of conditions: obesity, type 2 diabetes, congenital heart disease, cardiomyopathies, arrhythmias, long QT syndrome, pulmonary hypertension, congenital diaphragmatic hernia, intellectual disability, autism, inherited metabolic disorders, breast cancer susceptibility, and rare neurological conditions including KAND. The breadth is partly an accident of the patient population (Chung's clinical service sees families with whatever rare or undiagnosed conditions present) and partly intentional (Chung's view is that the genetic architecture of common and rare disease is more continuous than separate).

Within that range, the lab has developed a particular methodological signature: each disease the lab takes on gets a longitudinal natural-history study, often launched in collaboration with a family-led foundation, with the explicit goal of producing the trial-ready outcome measures and the registry of identified patients that an eventual therapeutic program will need. The KAND study is the most-cited example. Similar structures exist for SPARK (autism), PCORI-funded congenital heart disease cohorts, and other conditions in the lab's portfolio.

The model is not original to the Chung Lab. The Cystic Fibrosis Foundation pioneered the registry-and-natural-history approach in the 1960s. What Chung's lab has demonstrated is that the model is replicable for ultra-rare conditions where the patient population is too small to support the kind of foundation infrastructure CFF built. A condition with 600 globally identified patients can still have a usable registry if the academic group running it is willing to do the unfunded work of building one, and if the family-led foundation supplying applicants funds part of the data collection.

KAND specifically

KIF1A-Associated Neurological Disorder is caused by heterozygous damaging mutations in KIF1A. The clinical phenotype includes spastic paraplegia, intellectual disability, microcephaly, optic atrophy, and a progressive course in many cases. The disease was first molecularly characterized in 2011, and the patient-facing foundation, KIF1A.org, was incorporated by affected families in 2016.

Chung began collaborating with KIF1A.org shortly after the foundation's founding. The Chung Lab established the KAND Natural History Study, recruited patients globally, and began publishing genotype-phenotype correlations and trial-ready outcome measures. The lab's published work includes the largest single-cohort analyses of KAND clinical course and the development of MRI biomarkers for monitoring disease progression.

In parallel with the natural-history work, Chung's group launched a therapeutic program targeting KAND through antisense oligonucleotides designed to reduce expression of the mutant KIF1A allele while preserving the wild-type. The first patient enrolled in the resulting n-of-1 ASO trial began intrathecal dosing in approximately 2024, with safety and biomarker results being collected. The trial design is informed by the natural-history data the same lab has spent eight years building. The control arm is the patient's own pre-treatment trajectory documented in the registry.

Why the natural-history-first argument works

Three observations from the KAND program illustrate why Chung's approach matters for the broader n-of-1 field.

The first is patient identification. A program developing a therapy for an ultra-rare condition needs to find the patients who are eligible. For KAND, the natural-history registry is the patient-finding mechanism. When the n-of-1 ASO trial opened, the candidates were already known. The registry is not just a passive data collection effort; it is the recruitment infrastructure.

The second is outcome measurement. A condition with 600 affected individuals globally has no FDA-validated clinical endpoint. The Chung Lab has developed and published candidate outcome measures specific to KAND, drawing on the natural-history cohort. When the FDA reviews the n-of-1 trial protocol, the proposed endpoints are anchored in the same dataset the trial's eventual interpretation will rely on. This is what makes the regulatory case workable for a one-patient program.

The third is family infrastructure. KIF1A.org, KAND parents, and Chung's lab now constitute a tightly integrated network for any new therapy program. The foundation funds part of the work, the families participate in the registry, the lab does the science, and the trial infrastructure is shared. Building this network took Chung's group nearly a decade. Replicating it for the next condition takes most of a decade too. Foundation-led programs that try to skip the natural-history step usually find themselves rebuilding it later under time pressure.

Pediatrics chair as a structural choice

Chung's 2023 move to Chair of Pediatrics at Boston Children's, while keeping the Chung Lab and its natural-history programs running, has structural implications for the n-of-1 field. Boston Children's has the institutional infrastructure for individualized therapy programs (the Yu Lab, the genetics core, the GMP manufacturing relationships, the regulatory affairs experience), and Chung's chair-level role aligns the hospital's pediatrics strategy with the kind of long-horizon, foundation-partnered, natural-history-first work her lab has been doing.

The combination matters because the institutional gap between Boston Children's research operation and its clinical pediatrics service was the gap that made earlier rare-disease research at the hospital harder to translate. With Chung as chair, the gap is narrower. The KAND program, the milasen-class ASO programs in the Yu Lab, and the next decade of n-of-1 work at Boston Children's are now operating inside an institutional structure designed to support them.

Recognition

Chung's recognition has come through a steady accumulation of named professorships and elected memberships rather than a single transformative award. She is a member of the National Academy of Medicine. She has held the Kennedy Family Chair in Pediatrics at Columbia and now leads the Boston Children's pediatrics department. Her published work has been cited tens of thousands of times across the obesity, autism, congenital heart, and rare-disease literatures.

The recognition pattern reflects the work. Natural-history studies and patient registries do not produce single-paper breakthroughs. They produce a steady accumulation of cohort data that becomes the substrate other groups build on. Chung has been building substrate for thirty years. The n-of-1 era is the era when the substrate starts to matter visibly outside the genetics community.